Search clinical trials for: ABBV-453

Total 305 results

AbbVie

Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Relapsed/Refractory Multiple Myeloma

United States, Australia, Israel, United Kingdom
AbbVie

Not yet recruiting

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
AbbVie

Completed

Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

ABBV-154

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites

Hypertension | Congestive Heart Failure

Switzerland
Hutchmed

Recruiting

Phase 2 Study of HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Advanced Intrahepatic Cholangiocarcinoma

China
Hutchison Medipharma Limited

Recruiting

HMPL-453 in Advanced Malignant Mesothelioma

Advanced Malignant Mesothelioma

China
Hutchison Medipharma Limited

Unknown

A Study of HMPL-453 in Patients With Advanced Solid Malignancies

Solid Tumor, Adult

China
Hutchison Medipharma Limited

Terminated

A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies

Solid Tumor

Australia
AbbVie

Completed

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

Healthy Volunteer

United States
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Hypertension

France
AbbVie

Completed

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

Cystic Fibrosis

United States, Belgium, Canada, Czechia, France, Hungary, Netherlands, New Zealand, Poland, Slovakia, United Kingdom, Serbia
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453

Hypertension | Chronic Heart Failure
Calico Life Sciences LLC

Available

Expanded Access to ABBV-CLS-484

Advanced Solid Tumor Cancer
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 5-453 and Its Metabolites

Hypertension | Chronic Heart Failure

France
Bial - Portela C S.A.

Completed

Bioavailability Study of BIA 5-453

Hypertension | Congestive Heart Failure

France
AbbVie

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

Healthy Volunteers

United States
AbbVie

Completed

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

CoronaVirus Disease-2019 (COVID-19)

United States, Hungary, Israel, Netherlands, Puerto Rico
AbbVie

Terminated

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Merit E. Cudkowicz, MD
Calico Life Sciences LLC

Enrolling by invitation

HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262

Amyotrophic Lateral Sclerosis

United States
Pfizer

Completed

A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1

HIV-1

United Kingdom, South Africa, Australia, Canada, Italy, Poland, Switzerland, Argentina, Mexico
AbbVie

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Healthy Volunteers | Generalized Anxiety Disorder (GAD) | Bipolar Disorder (BPD)

United States
AbbVie

Completed

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

Human Immunodeficiency Virus (HIV)

United States, Puerto Rico
AbbVie

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

Psoriasis

United States
Molnlycke Health Care AB

Completed

A Multicenter, Post Marketing Clinical Follow up (PMCF) Investigation to Evaluate the Performance and Safety of a Soft Silicone Foam Dressing and to Evaluate the Performance of Standard Care in Exuding Venous Leg Ulcers

Venous Leg Ulcer (VLU)

Czech Republic
AbbVie

Active, not recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers

B-cell Lymphoma

Israel, Puerto Rico, Turkey
AbbVie

Completed

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, France, Japan, Puerto Rico, Spain, Taiwan
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453

Hypertension | Chronic Heart Failure

France
AbbVie

Withdrawn

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

Parkinson's Disease

United States, Puerto Rico
Stemcentrx

Terminated

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Ovarian Cancer

United States
AbbVie

Active, not recruiting

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease (Abroad)

Alzheimer's Disease (AD)

United States, Australia, Germany, Japan, New Zealand, Spain, United Kingdom
AbbVie

Active, not recruiting

A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants

Healthy Volunteers

United States
AbbVie

Terminated

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

Healthy Volunteers

United States
AbbVie

Completed

A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor (M23-492 FE)

Healthy Volunteers

United States
AbbVie

Terminated

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

Healthy Volunteers

United States
AbbVie

Completed

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Japan, Korea, Republic of, Taiwan
Hutchison Medipharma Limited

Recruiting

HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

Solid Tumor

China
AbbVie

Recruiting

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382

Human Immuno-deficiency Virus (HIV) Disease

United States, Puerto Rico, Japan, Spain, Germany, Canada, Belgium, France, Poland, South Africa, Italy
AbbVie

Recruiting

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Solid Tumors

United States, Israel, Japan
AbbVie

Not yet recruiting

Study to Assess Adverse Events and How Intravenously (IV) Infused ABBV-400 Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer

Colorectal Cancer
AbbVie

Recruiting

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States, Israel
AbbVie

Completed

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

Healthy Volunteers

United States
AbbVie

Terminated

A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

Cancer | Non Small Cell Lung Cancer | Acute Myeloid Leukemia (AML)

United States, France, Israel, Japan, United Kingdom
AbbVie

Terminated

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Cancer | Multiple Myeloma (MM)

United States, Australia, France, Israel, Japan, Spain, Taiwan
AbbVie

Terminated

A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer

Acute Myeloid Leukemia (AML)

United States
Calico Life Sciences LLC
AbbVie

Recruiting

Study of [14C] ABBV-CLS-7262 in Healthy Male Volunteers Following Single Oral Dose Administration

Healthy Volunteer

United States
AbbVie

Recruiting

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel
AbbVie

Terminated

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Cystic Fibrosis (CF)

United States, Australia, Belgium, Hungary, Netherlands, New Zealand, Slovakia, United Kingdom
AbbVie

Recruiting

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Alzheimer's Disease (AD)

United States
AbbVie

Terminated

A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease (AIM-CD)

Crohn's Disease

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Slovakia, Spain, Taiwan, United...
AbbVie

Terminated

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

Psoriasis

United States

3

Subscribe